Synthetic lethality by co-targeting mitochondrial apoptosis and PI3K/Akt/mTOR signaling

Mitochondrion

Volumn 19, Issue Part A, 2014, Pages 85-87

  Fulda, Simone ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Apoptosis; BH3 mimetics; Cell death; Mitochondria; PI3K Akt mTOR

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; AZD 8055; BH3 PROTEIN; BIM PROTEIN; BUPARLISIB; DACTOLISIB; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; NAVITOCLAX; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN MCL 1; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BURKITT LYMPHOMA; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL MEMBRANE PERMEABILITY; DRUG MECHANISM; DRUG POTENTIATION; LYMPHOMA; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; OLIGOMERIZATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RHABDOMYOSARCOMA CELL; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR XENOGRAFT; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; NEOPLASMS; PHYSIOLOGY;

APOPTOSIS; HUMANS; MITOCHONDRIA; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; TOR SERINE-THREONINE KINASES;

EID: 84911387339     PISSN: 15677249     EISSN: 18728278     Source Type: Journal    
DOI: 10.1016/j.mito.2014.04.011     Document Type: Article

References (21)

1. Ackler S., Xiao Y., Mitten M.J., Foster K., Oleksijew A., Refici M., Schlessinger S., Wang B., Chemburkar S.R., Bauch J., Tse C., Frost D.J., Fesik S.W., Rosenberg S.H., Elmore S.W., Shoemaker A.R. ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol. Cancer Ther. 2008, 7:3265-3274.
2. Benjamin D., Colombi M., Moroni C., Hall M.N. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat. Rev. Drug Discov. 2011, 10:868-880.
3. Chen S., Dai Y., Harada H., Dent P., Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res. 2007, 67:782-791.
4. Chresta C.M., Davies B.R., Hickson I., Harding T., Cosulich S., Critchlow S.E., Vincent J.P., Ellston R., Jones D., Sini P., James D., Howard Z., Dudley P., Hughes G., Smith L., Maguire S., Hummersone M., Malagu K., Menear K., Jenkins R., Jacobsen M., Smith G.C., Guichard S., Pass M. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 2010, 70:288-298.
5. Engelman J.A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 2009, 9:550-562.
6. Folkes A.J., Ahmadi K., Alderton W.K., Alix S., Baker S.J., Box G., Chuckowree I.S., Clarke P.A., Depledge P., Eccles S.A., Friedman L.S., Hayes A., Hancox T.C., Kugendradas A., Lensun L., Moore P., Olivero A.G., Pang J., Patel S., Pergl-Wilson G.H., Raynaud F.I., Robson A., Saghir N., Salphati L., Sohal S., Ultsch M.H., Valenti M., Wallweber H.J., Wan N.C., Wiesmann C., Workman P., Zhyvoloup A., Zvelebil M.J., Shuttleworth S.J. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem. 2008, 51:5522-5532.
7. Fulda S. Tumor resistance to apoptosis. Int. J. Cancer 2009, 124:511-515.
8. Fulda S., Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat. Rev. Drug Discov. 2012, 11:109-124.
9. Fulda S., Galluzzi L., Kroemer G. Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov. 2010, 9:447-464.
10. Konopleva M., Contractor R., Tsao T., Samudio I., Ruvolo P.P., Kitada S., Deng X., Zhai D., Shi Y.-X., Sneed T., Verhaegen M., Soengas M., Ruvolo V.R., McQueen T., Schober W.D., Watt J.C., Jiffar T., Ling X., Marini F.C., Harris D., Dietrich M., Estrov Z., McCubrey J., May W.S., Reed J.C., Andreeff M. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006, 10:375-388.
11. Ma X.M., Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 2009, 10:307-318.
12. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., Bruncko M., Deckwerth T.L., Dinges J., Hajduk P.J., Joseph M.K., Kitada S., Korsmeyer S.J., Kunzer A.R., Letai A., Li C., Mitten M.J., Nettesheim D.G., Ng S., Nimmer P.M., O'Connor J.M., Oleksijew A., Petros A.M., Reed J.C., Shen W., Tahir S.K., Thompson C.B., Tomaselli K.J., Wang B., Wendt M.D., Zhang H., Fesik S.W., Rosenberg S.H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
13. Preuss E., Hugle M., Reimann R., Schlecht M., Fulda S. Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 Protein. J. Biol. Chem. 2013, 288:35287-35296.
14. Qian J., Zou Y., Rahman J.S., Lu B., Massion P.P. Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung. Mol. Cancer Ther. 2009, 8:101-109.
15. Souers A.J., Leverson J.D., Boghaert E.R., Ackler S.L., Catron N.D., Chen J., Dayton B.D., Ding H., Enschede S.H., Fairbrother W.J., Huang D.C., Hymowitz S.G., Jin S., Khaw S.L., Kovar P.J., Lam L.T., Lee J., Maecker H.L., Marsh K.C., Mason K.D., Mitten M.J., Nimmer P.M., Oleksijew A., Park C.H., Park C.M., Phillips D.C., Roberts A.W., Sampath D., Seymour J.F., Smith M.L., Sullivan G.M., Tahir S.K., Tse C., Wendt M.D., Xiao Y., Xue J.C., Zhang H., Humerickhouse R.A., Rosenberg S.H., Elmore S.W. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 2013, 19:202-208.
16. Spender L.C., Inman G.J. Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics. Mol. Cancer Res. 2012, 10:347-359.
17. Tait S.W., Green D.R. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat. Rev. Mol. Cell Biol. 2010, 11:621-632.
18. Thomas L.W., Lam C., Edwards S.W. Mcl-1; the molecular regulation of protein function. FEBS Lett. 2010, 584:2981-2989.
19. van Delft M.F., Wei A.H., Mason K.D., Vandenberg C.J., Chen L., Czabotar P.E., Willis S.N., Scott C.L., Day C.L., Cory S., Adams J.M., Roberts A.W., Huang D.C. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006, 10:389-399.
20. Zheng L., Yang W., Zhang C., Ding W.J., Zhu H., Lin N.M., Wu H.H., He Q.J., Yang B. GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1. Cancer Lett. 2011, 309:27-36.
21. Zoncu R., Efeyan A., Sabatini D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2011, 12:21-35.